Absolute Antibody Ltd生物仿制藥抗體 重組蛋白
北京諾博萊德公司經(jīng)銷(xiāo)Absolute Antibody Ltd品牌，下面簡(jiǎn)單介紹一個(gè)公司。
Absolute Antibody Ltd是英國(guó)牛津大學(xué)Hutchings博士和Barclay教授創(chuàng)辦的第二代抗體公司，主要運(yùn)用基因工程技術(shù)和專(zhuān)業(yè)純化技術(shù)生產(chǎn)多種工程抗體和蛋白，可以在兩周內(nèi)提供100mg級(jí)的工程化抗體，與傳統(tǒng)技術(shù)生產(chǎn)的抗體相比，AbAbs抗體氨基酸序列明確，不含動(dòng)物成分，且批次間穩(wěn)定，消除因補(bǔ)體和Fc受體造成的背景，使結(jié)果更干凈。該公司的成立順應(yīng)了Nature雜志為首的科學(xué)界提倡改變目前抗體供應(yīng)混亂狀況的時(shí)代潮流。
主要產(chǎn)品產(chǎn)品介紹
l 科研用生物仿制藥抗體。
l 嵌合單克隆抗體。
l 用于體內(nèi)實(shí)驗(yàn)的重組抗體。
l 表位標(biāo)簽。
l 重組非IgG同型對(duì)照。
l 重組蛋白（Fc融合蛋白）。
北京諾博萊德科技有限公司 經(jīng)銷(xiāo)Absolute Antibody Ltd產(chǎn)品 貨期穩(wěn)定 優(yōu)勢(shì)訂購(gòu) 折扣好
下面是公司的部分熱銷(xiāo)產(chǎn)品
熱銷(xiāo)產(chǎn)品 | 貨號(hào) | 規(guī)格 |
Anti-EGFR [C225 (Cetuximab)] | Ab00279-10.0 | 200 ug |
Anti-EGFR [C225 (Cetuximab)] | Ab00279-10.0-BT | 1 mg |
Anti-EGFR [C225 (Cetuximab)] | Ab00279-9.1 | 200 ug |
Anti-DNA/RNA G-quadruplex (and related small molecules) [BG4] | Ab00174-1.1 | 100 ug |
Anti-EGFRvIII [L8A4] | Ab00184-1.1 | 200 ug |
Anti-Flavivirus group antigen [D1-4G2-4-15 (4G2)] | Ab00230-2.0 | 200 ug |
Anti-PGE2 [mAbPGE] | Ab00484-1.1 | 200 ug |
Anti-EGFRvIII [L8A4] | Ab00184-23.0 | 200 ug |
Anti-NS1 [22NS1 ] | Ab00675-23.0 | 200 ug |
Anti-DNA/RNA G-quadruplex (and related small molecules) [BG4] | Ab00174-24.1 | 100 ug |
Anti-Envelope protein [ZKA64] | Ab00779-10.0 | 200 ug |
Anti-Envelope protein [ZKA78] | Ab00780-10.0 | 200 ug |
Anti-CD41 [7E3 (Abciximab)] | Ab00282-10.3 | 200 ug |
Anti-CD40 [G28.5] | Ab00129-15.0 | 50 ug |
Anti-Folate receptor beta [CL10] | Ab00498-1.1 | 200 ug |
Anti-CD19 [FMC63] | Ab00613-30.11 | 50 ug |
Anti-DNA/RNA G-quadruplex (and related small molecules) [BG4] | Ab00174-10.6 | 100 ug |
Anti-erbB-2 (Her-2/neu) [4D5-8 (trastuzumab)] | Ab00103-10.0 | 200 ug |
Anti-SAG1 [Tox203] | Ab00444-1.1 | 200 ug |
Anti-CD4 epitope A [YTS 177.9] | Ab00205-2.0 | 200 ug |
Anti-EGFR [L3 11D] | Ab00455-2.0 | 200 ug |
Anti-V5 epitope tag [SV5-P-K] | Ab00136-5.0 | 200 ug |
Anti-(6-4) DNA photoproducts [64M-5] | Ab00227-1.1 | 200 ug |
Anti-AdiC [Fab21] | Ab00407-1.1 | 200 ug |
Anti-Thyroglobulin [aThy-29] | Ab00480-10.0 | 200 ug |
Anti-alpha-4 integrin [21.6] | Ab00644-1.1 | 200 ug |
Anti-CD200R [OX-102] | Ab00566-1.1 | 200 ug |
Anti-CD72 [BU40] | Ab00831-23.0 | 200 ug |
Anti-DR5 [H-48-2] | Ab00986-10.0 | 200 ug |
Anti-CD32 [AT130-5] | Ab01055-1.32-BT | 500 ug |
Anti-CD68 [FA-11] | Ab01113-7.1-BT | 1 mg |
Anti-Heparanase [22D9] | Ab01217-10.3 | 200 ug |
Anti-CD4 [MT310] | Ab00217-35.0-BT | 1 mg |
Anti-Testosterone [3T16] | Ab00819-8.1 | 200 ug |
Anti-CD40L [AT161-10] | Ab00873-10.0 | 200 ug |
Anti-CD8 [G10-1] | Ab00907-13.12-BT | 1 mg |
Anti-Hepatitis A virus capsid [R10] | Ab00933-1.1-BT | 1 mg |
Anti-CEA [EB-011] | Ab01002-23.0-BT | 1 mg |
Anti-kappa light chain [NH3/41.34] | Ab00855-1.1 | 200 ug |
Anti-TNFalpha [2TY] | Ab01123-10.3-BT | 1 mg |
Anti-polymorphic epithelial mucin [CTM01] | Ab01166-10.3 | 200 ug |
Anti-Vesicular stomatitis virus nucleoprotein N [VHH-1004] | Ab01244-10.9-BT | 1 mg |
Anti-IGF1R [IGFR 24-31] | Ab01286-23.0-BT | 1 mg |
Anti-BCL2 [bcl-2/100] | Ab01321-23.0-BT | 1 mg |
Anti-CEACAM1 [B3-17] | Ab01369-1.1 | 200 ug |
Anti-Maltose Binding protein [93/7] | Ab01423-3.0 | 200 ug |
Anti-high MWT epithelial antigens [KC4G3] | Ab01485-23.0-BT | 1 mg |
Anti-HLA Class 1 [W6/32] | Ab00114-2.0-BT | 1 mg |
Anti-Unknown Specificity (Isotype control) [MOPC-21] | Ab00178-8.4-BT | 1 mg |
Anti-SARS-CoV S glycoprotein [S124] | Ab00258-23.0-BT | 1 mg |
會(huì)員_a.png)